Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 87 P2 | DOI: 10.1530/endoabs.87.P2

UKINETS2022 Poster Presentations (15 abstracts)

PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK

Mohid Khan 1 , Louise Davies 2 , Melissa Back 3 , Tahir Shah 4 , Mark Pritchard 5 , Kathryn Cook 6 , Diana Hull 4 , Gail McKane 5 , Melissa Day 5 , Anne-Sophie Grandoulier 7 & Kate Higgs 8

1Cardiff and Vale University Health Board, Cardiff, United Kingdom; 2University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom; 3Royal Free London NHS Foundation Trust, London, United Kingdom; 4University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; 5Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom; 6Cardiff & Vale University Health Board, Cardiff, United Kingdom; 7Ipsen, Boulogne Billancourt, France; 8Ipsen, Slough, United Kingdom

Introduction: LAN, a somatostatin analogue, is a common first-line treatment for NETs. LAN comes as a pre-filled, ready-to-use syringe, administered every 4 weeks. In the UK, patients may receive LAN at home. The aim of PREF-NET was to generate real-world evidence describing patient’s experience of LAN administered in homecare and hospital settings, and the associated impact of treatment setting on other areas of patients’ lives.

Methods: PREF-NET was a multicentre, cross-sectional, patient-reported study of adults with GEP-NETs in the UK. The study had two parts: a quantitative online patient outcomes survey, and qualitative semi-structured interviews with a subgroup of respondents; here we report data from the online survey. Eligible patients (target, 80–90 patients across five clinical sites) were ≥18 years with GEP-NETs receiving a stable dose of LAN at home, but with recent experience in the hospital setting (switched to homecare 4–24 months earlier). The primary endpoint was overall patient preference for LAN administration at home versus the hospital setting. Secondary endpoints related to impact of treatment setting on healthcare utilisation, societal cost, work productivity, activities of daily living, and health-related quality of life.

Results: The study included 80 patients (mean age 63.9 years [SD 10.6]; 52.0% male. Participants had switched to homecare <6 months (29.5%), 6–12 months (29.5%) or >12 months (41.0%) prior to the study. In the primary endpoint analysis, 98.7% (95% CI 96.1-100.0) of participants preferred homecare (vs 1.3% [0.0–3.9] who preferred hospital care). Overall, 84.2% of participants reported that switching to homecare improved overall injection experience while 14.5% reported no change; additional secondary endpoints are reported in table.

Homecare vs hospitalSomewhat/much better (%)
Time (travel, attending appointments)93.6
Confidence in self-management76.3
Ability to plan/go on holiday80.3
Ability to engage in social activities73.7
Relationships with family members/friends55.3
Ability to work55.4

Conclusions: In this survey, all but one patient with GEP-NETs receiving LAN preferred to receive their treatment at home versus in hospital, with most indicating that homecare had a positive impact on many other areas of their lives.

Article tools

My recent searches

No recent searches.